Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 158 participants.

Also called NCT02392559

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 158 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02392559
  • EudraCT 2014-002277-11
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Belgium, Brazil, Canada, Colombia, Czechia, Finland, Greece, Hungary, Italy, Malaysia, Netherlands, New Zealand, Norway, Poland, Portugal, Russia, Slovenia, South Africa, Spain, Switzerland, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02392559. Randomized; triple masking; primary purpose treatment. Start 2016-03-24 (actual); primary completion 2019-11-25 (actual). Results posted on 2020-07-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders
Acronym
HAUSER-RCT
Condition
Heterozygous Familial Hypercholesterolemia
Intervention (Drug)
Evolocumab
Intervention (Drug)
Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct02392559
Content hash
f2130d903cf68cc628c19ad9339f69070ee3760002a3ef6f4dbfa9c228e56297